We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
-0.04%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$304M
AUM Growth
+$1.15M
Cap. Flow
+$57.5M
Cap. Flow %
18.92%
Top 10 Hldgs %
41.92%
Holding
84
New
27
Increased
13
Reduced
15
Closed
15

Top Buys

1
KRYS icon
Krystal Biotech
KRYS
+$7.32M
2
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$4.48M
3
TARS icon
Tarsus Pharmaceuticals
TARS
+$4.42M
4
SLRN
ACELYRIN
SLRN
+$4.25M
5
AMAM
Ambrx Biopharma Inc
AMAM
+$3.91M

Top Sells

1
AKRO
Akero Therapeutics
AKRO
+$11.4M
2
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$8.67M
3
APLS
Apellis Pharmaceuticals
APLS
+$7.91M
4
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$7.08M
5
PCVX icon
Vaxcyte
PCVX
+$6.91M

Sector Composition

1 Healthcare 67.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACAD icon
51
Acadia Pharmaceuticals
ACAD
$4.38B
$1.67M 0.55%
+80,000
New +$2.17M
LEGN icon
52
Legend Biotech
LEGN
$4.31B
$1.51M 0.5%
+22,500
New +$1.56M
QURE icon
53
uniQure
QURE
$2.77B
$1.44M 0.47%
215,000
– –
RCUS icon
54
Arcus Biosciences
RCUS
$3.44B
$1.35M 0.44%
75,000
– –
TVTX icon
55
Travere Therapeutics
TVTX
$5.27B
$1.34M 0.44%
+150,000
New +$2.12M
ARGX icon
56
argenx
ARGX
$53.8B
$1.23M 0.4%
+2,500
New +$1.22M
VTYX
57
DELISTED
Ventyx Biosciences
VTYX
$1.22M 0.4%
+35,000
New +$1.21M
WHWK
58
Whitehawk Therapeutics
WHWK
$192M
$1.21M 0.4%
250,000
– –
KALV
59
DELISTED
KalVista Pharmaceuticals
KALV
$963K 0.32%
+100,000
New +$1.02M
BMEA icon
60
Biomea Fusion
BMEA
$92.5M
$894K 0.29%
65,000
-125,000
-66% -$2.25M
ROIV icon
61
Roivant Sciences
ROIV
$24.8B
$748K 0.25%
64,000
– –
VRNA
62
DELISTED
Verona Pharma
VRNA
$734K 0.24%
45,000
-65,000
-59% -$1.25M
INBX
63
DELISTED
Inhibrx, Inc. Common Stock
INBX
$642K 0.21%
35,000
– –
FUSN
64
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$633K 0.21%
243,287
-169,412
-41% -$543K
ABOS icon
65
Acumen Pharmaceuticals
ABOS
$163M
$623K 0.2%
+150,000
New +$927K
ETNB
66
DELISTED
89bio
ETNB
$463K 0.15%
+30,000
New +$504K
RNAM
67
DELISTED
Avidity Biosciences
RNAM
$415K 0.14%
65,000
– –
RAIN
68
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$280K 0.09%
325,000
– –
MRSN
69
DELISTED
Mersana Therapeutics
MRSN
$77.8K 0.03%
2,450
– –
APLS
70
DELISTED
Apellis Pharmaceuticals
APLS
– –
-180,000
Closed -$7.91M
BCRX icon
71
BioCryst Pharmaceuticals
BCRX
$2.36B
– –
-200,000
Closed -$1.41M
BTAI icon
72
CALL
BioXcel Therapeutics
BTAI
$27.4M
– –
-8,125
Closed -$866K
KYNB
73
Kyntra Bio
KYNB
$29.3M
– –
-1,460
Closed -$98.5K
INCY icon
74
Incyte
INCY
$23.4B
– –
-65,000
Closed -$4.05M
IOVA icon
75
Iovance Biotherapeutics
IOVA
$2.23B
– –
-100,000
Closed -$704K
1 2
3
4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q3 2023 Portfolio in Review

As of Q3 2023, Ghost Tree Capital held 84 positions worth $304M, up 0.38% from $303M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Ghost Tree Capital deployed $57.5M of net new capital in Q3 2023, opening 27 new positions and adding to 13 existing holdings. Its largest new stake was Deciphera Pharmaceuticals, Inc. Common Stock: 325,000 shares worth $4.13M.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 91% a quarter earlier.

On the sell side, the largest reduction was Akero Therapeutics, an estimated $11.4M trimmed.

  • Ghost Tree Capital's largest Q3 2023 buy was Deciphera Pharmaceuticals, Inc. Common Stock: 325,000 shares worth $4.13M.
  • Ghost Tree Capital added most to Krystal Biotech in Q3 2023, an estimated $7.32M increase.
  • Ghost Tree Capital's biggest Q3 2023 reduction was Akero Therapeutics, cutting an estimated $11.4M.
  • Ghost Tree Capital fully exited Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2023, selling an estimated $8.67M.
  • Ghost Tree Capital's ten largest holdings make up 42% of its $304M portfolio in Q3 2023.
  • Ghost Tree Capital opened 27 new positions and closed 15 in Q3 2023.
  • Ghost Tree Capital's portfolio value rose 0.38% quarter-over-quarter to $304M.

Based on Ghost Tree Capital's 13F filing for Q3 2023, filed 14 Nov 2023.